- Home
- WKSP vs CMMB Comparison
WKSP vs CMMB Comparison
Compare WKSP & CMMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WKSP | CMMB |
|---|---|---|
| Founded | 2003 | 2004 |
| Country | United States | Israel |
| Employees | 81 | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.2M | 11.2M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | WKSP | CMMB |
|---|---|---|
| Price | $1.01 | $1.58 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 1 |
| Target Price | $9.25 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 188.0K | 47.1K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 101.67 |
| EPS | N/A | ★ 0.04 |
| Revenue | N/A | N/A |
| Revenue This Year | $133.45 | N/A |
| Revenue Next Year | $24.01 | N/A |
| P/E Ratio | ★ N/A | $39.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $0.87 |
| 52 Week High | $4.90 | $3.86 |
Technical Indicators
Market Signals| Indicator | WKSP | CMMB |
|---|---|---|
| Relative Strength Index (RSI) | 35.30 | 42.83 |
| Support Level | N/A | $1.48 |
| Resistance Level | $1.44 | $1.64 |
| Average True Range (ATR) | 0.12 | 0.18 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 16.18 | 14.00 |
Price Performance
Historical ComparisonAbout WKSP Worksport Ltd.
Worksport Ltd through its subsidiaries, designs, develops, manufactures, and owns the IP on a variety of tonneau covers, solar integrations, and NP (Non-Parasitic), Hydrogen-based true green energy solutions for the sustainable, clean energy, and automotive industries. The company's product includes soft vinyl tonneau covers and hard aluminum tonneau covers. It operates in two reporting segments for financial reporting purposes: Hard Tonneau Covers and Soft Tonneau Covers. Geographically, the company operates in Canada, United States and Other Countries.
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.